By Razak Musah Baba
LONDON--AstraZeneca PLC (AZN.LN) and Amgen Inc. (AMGN) said
Monday that the Phase III AMAGINE-1 study evaluating brodalumab in
patients with moderate-to-severe plaque psoriasis met all primary
and secondary endpoints for both evaluated doses.
The companies said a significantly higher proportion of patients
treated with brodalumab achieved a PASI 75 response, or primary
endpoint, as well as PASI 90 and PASI 100 responses at week 12,
secondary endpoints, compared to a placebo.
"Data from the AMAGINE-1 study suggest that brodalumab may offer
a new level of efficacy for patients with moderate-to-severe plaque
psoriasis, a disease that affects more than 100 million people
globally," said Sean E. Harper, executive vice president of
research and development at Amgen.
"Moderate-to-severe plaque psoriasis is a serious disease, and
despite available treatments, there is still a significant need for
more effective therapies," Briggs Morrison, executive vice
president of global medicines development at AstraZeneca,
added.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter:
@Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires